



## News Release

### Suven's PAT up by 367% for the year ended March 2014 & proposed regular and one time special silver jubilee year dividend aggregating to 250%

HYDERABAD, INDIA (22/ May' 2014) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, and Contract Research and Manufacturing Services (CRAMS) company which is **celebrating its silver jubilee year of operations** today announced its audited financial results for the year ended 31<sup>st</sup> Mar 2014. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 22<sup>nd</sup> May 2014 at Hyderabad.

Financial Highlights for the 4<sup>th</sup> Quarter ended Mar' 2014:

Growth in revenue	Rs 1320 Mn vs. Rs 752 Mn	- Up by 75%
Growth in PAT	Rs 324 Mn vs. Rs 86 Mn	- Up by 275%
Growth in EBIDTA	Rs 486 Mn vs. Rs 141 Mn	- Up by 244%

Financial Highlights for the year ended Mar' 2014:

Growth in revenue	Rs 5133 Mn vs. Rs 2589 Mn	- Up by 98%
Growth in PAT	Rs 1442 Mn vs. Rs 308 Mn	- Up by 367%
Growth in EBIDTA	Rs 2221 Mn vs. Rs 542 Mn	- Up by 310%

The growth in profit during the year was due to the supply of pre-launch quantities of intermediates for 3 NCE's under CRAMS.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 479 Mn (9.387% on revenue) for the year ended March 31, 2014

The Board has proposed a Dividend of Re. 0.50 per share (50% of face value Rs. 1.00 each), with an additional Special Silver Jubilee year dividend of Rs. 2.00 per share (200% of face value of Rs. 1.00 each), aggregating to Rs 2.50 per share for the financial year 2013-14, subject to approval of the shareholders in the ensuing Annual General Meeting.

*SUVN D-4010 and SUVN G-3031 are undergoing IND enabling toxicological studies in USA in preparation for Phase 1 clinical trial. SUVN-502 undergoing phase 1b clinical trial in USA in preparation for Phase 2a (POC) study on patients in USA*

For more information on Suven please visit our Web site at <http://www.suven.com>

**Risk Statement:**

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;*